NemaLife Files a Patent for Novel Bioassay to Aid the Discovery of Functional Ingredients for Gut Health
The NemaLife team filed a provisional patent application on an innovative microfluidic in vivo bioassay to accelerate identifying ingredients that improve gut health. This groundbreaking assay is set to transform how we understand and enhance gut health, addressing critical issues related to leaky gut syndrome caused by aging, poor nutrition, and enteropathogenic infections. Read More
Corbion Develops Fermented Algae Ingredient for Pet Nutrition
There is a growing demand for Omega-3 fatty acids, such as docosahexaenoic acid (DHA), in pet food, which traditional fish oil sources cannot meet. Corbion’s sustainable AlgaPrime DHA P3 ingredient is a microalgae powder high in DHA and can be used in various pet food applications. Congrats to the Corbion team on this development! Read More
DSM-Firmenich to Illuminate Postbiotics and Proactive Health at SupplySide West
DSM-Firmenich recently acquired Adare Biome, a postbiotics company. DSM-Firmenich will be at SupplySide West in Las Vegas this month to showcase their solutions for improving cognitive performance and women’s health. We’re excited about the launch of their new postbiotic blend, Humiome Post LB, and their DHA ingredient for brain health. Read More
See us at the Microbiome R&D & Business Collaboration Forum
The 11th Microbiome R&D & Business Collaboration Forum and 5th Probiotics & Prebiotics Congress: USA kicks off on the 18th of October in San Diego. Dhaval Patel, Ph.D., our Director of Research and Innovation, will be presenting our latest assays for accelerating the discovery of new biotics, including our new leaky gut syndrome assay. Read More
'Zombie Cells' May be the Key to Curing for Alzheimer's Disease
Senescent cells that have stopped dividing but are not dead are called ‘Zombie Cells.’ They can accumulate in the body over time and contribute to aging and age-related diseases, such as Alzheimer’s. A new clinical trial is testing a drug that targets these cells as a treatment for Alzheimer’s. The trial is still ongoing, but early results have been promising. Read More